Last updated: March 22, 2024
Sponsor: Danish Headache Center
Overall Status: Active - Recruiting
Phase
N/A
Condition
Chronic Pain
Oral Facial Pain
Migraine (Pediatric)
Treatment
Levcromakalim
Ivabradine
Placebo
Clinical Study ID
NCT04853797
Ivabradine H-20061329
Ages 18-60 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Be able to give voluntary written informed consent to participate.
- Have a diagnosis of episodic migraine without aura according to The InternationalClassification of Headache Disorders 3rd Edition.
- Be in good general health and without any cardio- or cerebrovascular diseases,psychiatric disorders or other severe comorbidities.
- Be 18-60 years of age.
- Have a weight between 50-100 kg.
- Have a normal standard resting 12-lead ECG at the screening visit with heart rate (HR) ≥ 60 bpm (the inclusion criterium of HR ≥ 60 bpm at screening has previously been usedin studies with dosages of ivabradine up to 20 mg as single and multiple doses with nosignificant adverse events).
- Be without any chronic use of medicine.
- Have a negative urine-human chorionic gonadotropin (hCG) test at the screening visitif they are female of childbearing potential.
Exclusion
Exclusion Criteria:
- Suffer from tension type headache, as defined by the The International Classificationof Headache Disorders 3rd Edition, more than five days a month on average in the lastyear.
- Are diagnosed with any primary headache disorder apart from migraine without aura asde-fined in The International Classification of Headache Disorders 3rd Edition (relating to tension type headache, see above).
- Suffer from any headache 48 hours prior to the start of the experiment or any migraine 72 hours prior to the start of the experiment.
- Are allergic to ivabradine or levcromakalim.
- Are lactose intolerant (due to Ivabradine tablets containing lactose).
- Have a daily intake of any medicine other than oral contraception or use of drugs orother ed-ibles/beverages with potential serious interactions with ivabradine
- Have a history of personal/familial or clinical signs of: cardiovascular andcerebrovascular disease (Long QT Syndrome, Cardiac dysrhythmia, Bradycardia, i.e. aresting heart rate of < 60 bpm at screening, Amnestic information or clinical signs ofhyper- or hypotension (Hypertension (systolic blood pressure > 150 mmHg and / ordiastolic blood pressure > 100 mmHg)/Hypotension (systolic blood pressure < 90 mm Hgand / or diastolic blood pressure < 50 mmHg)), Heart failure (NYHA II or higher));Psychiatric conditions; Drug abuse of any kind; Smoking; Other comorbidities orclinical signs of diseases of any kind considered by the investigating physician tomake the participant ineligible because of safety concerns).
- Are pregnant, breastfeeding or not using appropriate contraception.
- Do not want any information on significant pathological findings in the study.
Study Design
Total Participants: 30
Treatment Group(s): 3
Primary Treatment: Levcromakalim
Phase:
Study Start date:
April 16, 2021
Estimated Completion Date:
January 01, 2025
Study Description
Connect with a study center
Rigshospitalet-Glostrup
Glostrup, Nordre Ringvej 57 2600
DenmarkActive - Recruiting
Danish Headache Centre, Rigshospitalet-Glostrup
Glostrup, Zealand 2600
DenmarkActive - Recruiting
Danish Headache Center
Glostrup, 2600
DenmarkActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.